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The range of usefulness of these preparations increased greatly after the 
discovery of new derivatives: promethazine in 1930 and chlorpromazine in 
1950. LABORIT's work (I 952) on the potentiation of anaesthetics by pheno-
thiazines and their hibernating action was largely responsible for the growing 
interest in these drugs. Other new preparations followed rapidly, so that there 
are at present about thirty in use and the number is steadily increasing. 
Structure 
Phenothiazine has a three-ringed structure in which two benzene rings are linked 
by a sulphur and a nitrogen atom. The positions 2 and I 0 are usually substituted. 
As the structural formula becomes more asymmetrical the drug becomes more 
potent. Substitution of a CF3 group in position 2 increases the antipsychotic 
action. 
The phenothiazines can be divided into three groups on the basis of the substi-
tution in position 10, theN atom (see Scheme. p. 4). The derivatives are: 
a. with aliphatic side chain: these are the least potent in their antipsychotic 
action: 
b. with piperidine in the side chain: these are more potent than group a in their 
antipsychotic action: 
c. with piperazine in the side chain: these are the most potent in their anti-
psychotic action. 
Action 
All phenothiazine derivatives have a sedative action. They do not only influence 
the central nervous system, like the barbiturates and other sedatives, but also 
affect other organs. These effects have been studied most extensively for chlor-
promazine. This preparation has no effect on the motor cortex but depresses the 
sensory cortex. The action of the thalamus is stimulated and the hypothalamus 
is depressed. The activity of the extra-pyramidal system is increased by chlor-
promazine, to a lesser extent this is also true for N. P. 207 and thioridazine. 
The action of chlorpromazine upon the brain stem reticular system appears to 
be complex. It only slightly raises the threshold of arousal produced by direct 
electrical stimulation of the brain stem. Judging by changes in the EEG, chlor-
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promazine very effectively blocks arousal produced by auditory and other types 
of peripheral stimulation (BRADLEY, 1963). 
This preparation has strong adrenergic and weaker peripheral cholinergic 
blocking activity. It decre3.ses the excretion in the urine of gonadotropins~ 
progesterone and oestrogens: it blocks ovulation. suppresses the oestrous cycle 
and causes infertility and pseudo-pregnancy. The drug has a diuretic action. 
The phenothiazines are readily absorbed both parenterally and from the 
digestive tract. Sixty to seventy per cent is removed from the portal circulation 
by the liver. Excretion by the kidney is very slow. In some cases various metabo-
lites and even free chlorpromazine could be found in the urine 6-12 months after 
the administration of the drug had been stopped. The excretion in the faeces of 
prochlorpromazine and trifluoperazine is much higher than that of chlorproma-
zine. the reason for this is probably the nature of the side chains. (GOODMAN & 
GILMAN, 1967; HAASE & JANSSEN. 1965). 
PERRY. CULLING, BERRY & HANSEN give the following account of the metabo-
lism of chlorpromazine: "Chlorpromazine is metabolized in man to form a wide 
variety of derivatives. The N-dimethylaminopropyl side chain can be either 
partially or completely dernethylated. or converted to the N-oxide. and the 
phenothiazine nucleus is subject to sulfoxidation and to ring hydroxylation. 
The hydroxylated or phenolic derivatives can in turn be conjugated with glucur-
onic or sulfuric acid. Since these alterations can occur singly or in combination, 
a large number of metabolites is possible theoretically ar.d sorr:e of these may 
not only account for the pharmacological activity of chlorpromazine but also 
for its varied toxic effects.· 
After absorption the phenothiazines spread rapidly to all parts of the body. 
They can be demonstrated, in order of decreasing concentration. in the lungs. 
liver, adrenal glands. spleen. brain ar,.d blood. 
POTTS in 1962. by means of experiments on rabbits. rats and hamsters. dis-
covered that the concentration of phenothiazine in the uveal tract is fifty times 
that in any other organ. The concentration in the choroid was the highest~ 
followed by the ciliary body and the iris. Albino rats did not exhibit the uveal-
concentration-phenomenon. In experiments in vitro with a phenothiazine 
derivative and a suspension of pigment granules from the uveal tract. the gran-
ules were found to absorb the phenothiazine derivative. POTTS concludes from 
this that the pigment granules are the place where the phenothiazines are stored 
in vivo. 
CASSANO et al. (1968) also demonstrated uveal con~entration in cats. 
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Side effects and toxic reactions 
The side effects which may be produced by chlorpromazine are palpitations~ 
faintness. nasal stuffiness. a dry mouth and slight constipation. These effects are 
not difficult to treat. On the other hand, the orthostatic hypotension which may 
occur after the administration of phenothiazines is sometimes very difficult to 
combat. Pharmacological over-activity may result in parkinsonism, dyskinesia 
and akathisia (AYD, 1961, 1963). 
Other toxic reactions of the phenothiazines include: ocular complications. 
leucocytosis. leucopenia. eosinophilia (HARTINETT. 1955: BACON, 1964),jaundice 
and skin reactions (HOLLISTER, 1964, 1965; IPPEN, 1962; JUNG eta!., 1963). 
Before paying further attention to the ocular complications (see P. 17) a 
survey of the phenothiazine derivatives in present use. together with their 
structural formulas and trade names. is given. 
For historical interest the structural formulas of phenothiazine itself, 
methylene blue and N. P. 207 are included. although they are no longer used 
therapeutically. 
Structural formulas 
phenothiazine 
Cl 
(CH3)2N (X~X) N(CH3)2 methylene blue 
N.P. 207 
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promazine 
I 0-(3-dimethylaminopropyl)-phenothiazine 
Prazine, Sparine. Protactyl, Yerophen. 
chlorpromazine 
2-chlor-10-(3-dimethylaminopropyl)-
phenothiazine 
Largactil. 4560 RP. Megaphen. Thorazine. 
Hibernal 
methopromazine (methoxypromazine) 
2-methoxy-1 0-(3-dimethylaminopropyl)-
phenothiazine 
Mopazine. Tentone 
acepromazine 
2-acetyl-1 0-(3-dimethylaminopropyl)-
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Plegicil. N otensil, Soprintin 
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triftupromazine 
2-trifluoromethyl-10-(3-dimethylamino-
propyl)-phenothiazine 
Siquil. PsyquiL Vesprin. Vespral. 
SKF 4648 
aminopromazine 
I 0-(2.3-bis-( dimethylamino )-propyl)-
phenothiazine 
Lorusil, Lispamol 
trimeprazine (alimemazine) 
!0-(3-dimethylamino-2-methyl-propyl)-
phenothiazine 
Nedeltran. Temaril. Th6ralE:ne. Panectyl. 
Repeltin. Vallergan 
laevomepromazine (methotrimeprazine) 
2-methoxy-1 0-(3-dimethylamino-2-methyl-
propyl)-phenothiazine 
Nozinan. 7044 RP. Neurocil. Veractil 
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promethazine 
10-(2-dimethy1aminopropyl)-phenothiazine 
Phenergan. 3277 RP. Atosil 
propiomazine 
2-propionyl-1 0-(2-dimethylaminopropyl)-
phenothiazine 
Largon. Wy-1359. Dorevane 
b. phenothiazines with a piperidine derivative in the side chain 
o:o 
cx:D-5-CH, 
I 
CH2 
I 
CHO 
GN-CH, 
mepazine (pecazine) 
10-(N-methyl-3-piperidylmethyl)-
phenothiazine 
Pacatal. Lacumin 
thioridazine 
2-methylmercapto-1 0-(N-methyl-2-
piperidylethyl)-phenothiazine 
Melleril. Mellaril 
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mesoridazine 
2-methylsulphinyl-1 0-(N-methyl-2-
piperidylethyl)-phenothiazine 
Serentil, TPS-23 
pipamazine 
2-chlor-1 0-(3-( 4-carbamoyl-piperidyl)-
propyl)-phenothiazine 
Mornidine 
piperacetazine 
2 -acety 1-1 0-(3-( 4-(~-hydroxyethyl )-
piperidine)-propyl)-phenothiazine 
Qui de. 
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cx:Dc~N 
I 
CH2 
I 
CH 2 
I 
CH2 
6 
OH 
propericiazine 
2-cyano-1 0-(3-(4- hydroxypiperidino)-
propyl)-phenothiazine 
Neuleptil, 8909 RP, Aolept 
c. phenothiazines with a piperazine (or piperazinyl) group in the side chain 
cx:D 
I 
CH2 I 
CH2 I 
CH2 
(~) 
~ 
CH3 
(X:X)cl 
I 
CH2 
I 
CH2 I 
CH2 I () 
N 
I CH, 
perazine 
I 0-(3-(1-methyl-4-piperazinyl)- propyl)-
phenothiazine 
Taxilan 
prochlorperazine {prochlorp6mazine) 
2-chlor-l 0-(3-(1-methyl-4-piperazinyl)-
propyl)-phenothiazine 
Stemetil, 6140 RP. Tementil, Nipodal, 
Compazine 
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CH3 
trifluoperazine 
2-trifluoromethyl-l 0-(3-(l-methyl-4-
piperazinyl)-propy1)-phenothiazine 
Terfluzine. Stelazine. Jatroneural 
thiethylperazine 
2-ethy1mercapto-1 0-(3-(l-methy1-4-
piperazinyl)-propyl)-phenothiazine 
Torecan 
thioproperazine 
2-dimethy1sulphamoy1-1 0-(3-(l-methy1-4-
piperazinyl)-propyl)-phenothivJne 
Majeptil. 7843 RP. Vontil 
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~ I 
CH 2 CH2 I I 
CH2 CH2 I I 
CH2 CH3 I C) 
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' CH 2 
c:J 
' CH2-CH2-0H 
cx:Dcs 
' CH 2 
' CH 2 
' CH 2 
' CJ ~ 
CH 2-CHiOH 
butyrylperazine 
2-butyryl-l 0-(3-(1-methyl-4-piperazinyl).-
propyl)-phenothiazine 
Randolectil 
perphenazine 
2-chlor-l 0-(3-( 1-hydroxyethyl-4-
piperaziny1)-propyl)-phenothiazine 
Trilafon. Decentan. Fentazin 
fluphenazine 
2-trifluoromethyl-1 0-(3-(l-hydroxyethyl-
4-piperazinyl)-propyl)-phenothiazine 
Sevinol. PermitiL Omca. Prolixin. Moditen 
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acetophenazine 
2-acetyl-1 0-(3-(1 -hydroxyethyl-4-
piperazinyl)-propyl)-phenothiazine 
Tindal 
c'H 0 carphenazine 
' ' CH, 
' CH, 
c) 
' CH -CH-OH 
' ' 
CX)Ocl 
' C,H 2 
C,H 2 
CH 2 I 
c:) 0 
I - II 
CH;CHiO-C-CH 3 
2-propionyl-1 0-(3-(l-hydroxyethyl-4-
piperaziny1)-propyl)-phenothazine 
Prokethazine, Wy-2445 
thiopropazate 
2-chlor-1 0-(3-(l-acetoxyethyl-4- piper-
azinyl)-propyl)-phenothiazine 
DartaL Dartilan. Dartalan 
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dixyrazine 
I 0-(3-( 1-hydroxyethyl-4-piperazinyl)-
2-methylpropyl)-phenothiazine 
Esucos 
2-trifluoromethyl-l 0-(3-( l-hydroxyethyl-
4-homopiperazinyl)-propyl)-phenothiazine 
Pasaden. D 775 
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13 
Damage to the eye caused by the administration of drugs has been recognized 
for a long: time. At the end of the last century and the beginning: of this. most 
attention was being: paid to arsenic. 
Toxic ef/ects of arsenic 
In 1907 ROBERT KOCH described 22 cases of blindness among 900 patients who 
had been treated with Atoxyl (a compound of arsenic) for sleeping sickness. 
Reduction of the visual field and anomalies in blue-yellow vision were also 
observed. In some cases atrophy of the optic nerve was found. 
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Pathological examination, performed by IGERSHEIJvrER in I 908 and 1909 and 
by BIRCH-HIRSCHFELD and KOSTER in 1910 (quoted by JESS.l92I ). revealed degener-
ation of the medullary sheaths of the optic nerve and of the ganglion cells and the 
nerve fibre layer of the retina. The nuclei of the rods also showed degenerative 
changes but the nuclei of the cones were apparently unaffected by the arsenic. 
Other compounds of arsenic. such as arsacetin, spirasyl. soamin. orsodan and 
indarso1, may cause similar damage to the retina and optic nerve. Salvarsan. 
however. is not known to have caused serious damage to the eye. 
Toxic effects of quinine and its derivarh·es 
At about the same time optochine (ethyl hydrocupeine). a quinine alkaloid. 
began to be used in cases of pneumo-. strepto- and staphylococcal infection. 
Blindness caused by this drug has been described. The pupils do not react to 
light and react poorly to convergence. The retinal aneries are narrow and the 
veins are wide. There is oedema of the retina round the disc and the macula 
lutea. Sometimes the periphery of the retina is patchily pigmented. In the course 
of time optic atrophy develops. 
Pathological examination shows that the nerve fibre layer of the retina has 
become thinner on the nasal side of the disc. The ganglion cells are degenerated 
throughout the retina, The walls of the small blood vessels. especially the adven-
titia. are thickened. The choroid is atrophied on the nasal side~ degeneration of 
the pigment epithelium and migration of pigment are seen. The optic nerve is 
atrophic. 
Both clinically and pathologically this picture resembles that of quinine 
intoxication. Here also marked loss of vision and oedema of the retina are found 
in the acute stage. The pupils are wide and do not react to Iight and only poorly 
to convergence. The voltage of the various components of the ERG and the 
standing potential- measured by way of the EOG- are low. Optic atrophy and 
narrowing of the blood vessels do not occur until later. Years after the acute 
onset the ERG and EOG are still clearly subnormal and the visual field is still 
markedly restricted: the visual acuity. however, usually returns to normal. It is 
now thought that quinine and its derivatives have a direct toxic action on the 
ganglion cells of the retina: formerly the vasoconstriction was thought to be the 
primary cause of the quinine amblyopia. 
Eucupine (iso-amyl hydrocupreine). another quinine alkaloid used in strepto-
and staphylococcal infections, can also cause similar lesions. 
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Optochine. quinine and eucupine have a quinoline nucleus in common: 
C,H,N: H!-AH H~N)H 
H 
In 1921 JESS experimented with quinoline on rabbits which developed a 
retinopathy. The fundus had a speckled appearance. with white areas and dark 
patches due to migration of pigment. The optic disc was pale and the arteries 
were extremely narrow. There were crystals on the retina. Histologically depig-
mentation of the pigment epithelium was seen, with migration of the pigment 
out of the epithelium, circumscribed areas of oedema in and between the nuclear 
layers of the retina and areas in which the rods and cones had disappeared. The 
nerve fibre layer and the ganglion cell layer were atrophic. as also was the optic 
nerve. In addition. a transitory cataract was seen in the lens. 
Irreversible cataract can be produced in rabbits by the injection of naphtha-
lene. The structural formula of this substance is very similar to that of quinoline~ 
only the N atom is replaced by a CH group: 
H(X)H  H 
H H 
H H 
naphthalene 
The fundus picture and the histological changes in the retina resemble closely 
those produced by quinoline. 
A quinoline group is also found in plasmochine. quinacrine, chloroquine. 
amodiaquine and hydroxychloroquine. Chloroquine and hydroxychloroquine 
especially are extensively used in the treatment of lupus erythematodes and 
rheumatism. 
Retinopathy resulting from chloroquine therapy was described in a publica-
tion by HOBBS. SORSBY & FREEDMAN in 1959. The signs and symptoms are loss of 
vision. temporal reduction of the visual field with paracentral scotomata, pale 
optic discs. narrowing of the retinal blood vessels. migration of pigment in the 
periphery of the fundus. and a ring of pigment round the fovea (bulrs eye). 
BUTLER (1966) pointed out that the first visible pigmentary disturbance appears. 
more frequently in the periphery than at the macula. 
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A lowered EOG is found in the cases with severe retinopathy. As the lower 
limit of normal BUTLER took a value of 185% for the rise in resting potential in 
light adaptation as percentage of the lowest value in dark adaptation (LP/DT 
ratio)~ it would appear subsequently. however. that this value is probably too 
high. 
Other ocular lesions caused by chloroquine are accommodative palsy and 
keratopathy. The accommodative palsy is usually transitory and occurs at the 
beginning of the treatment. The keratopathy often causes deterioration of vision. 
It affects the epithelium and is probably caused by chemical substances which 
are dissolved in the tears and become deposited on the cornea. Complete recov-
ery of the corneal epithelium always takes place if the administration of the 
drug is stopped: the retinal condition. however. is irreversible. 
Toxic effects of iodine compounds 
In 1926 SCHEERER described a case of puerperal sepsis in which acute severe loss 
-of vision occurred after the intravenous injection of I 00 cc. Septojod (a 10 x 
concentration of Pregfs solution). At first there was oedema of the retina. 
especially in the centre; later there was marked migration of pigment throughout 
the retina; the blood vessels were unaffected. 
The pigment was described by SCHEERER and by VON BONAU (1929) as resem-
bling coffee grounds. ROGGENKAMPER (1927) compared the fundus picture with 
that of retinitis pigmentosa and applied the treatment for that condition which 
was usual at that time: he gave an intravenous injection of a 10% lecithin solu-
tion and obtained a marked improvement of vision. SALLMANN (1933) and OHM 
(1934) and voN BONAU. however. also observed spontaneous improvement of 
this retinopathy. Disturbances of dark adaptation were not found. 
The histology of this retinopathy was described by RIEHM in 1927. He injected 
various quantities of Septojod into rabbits. Even where there were no visible 
changes macroscopically he found that the internal limiting membrane was 
raised by exudate in the underlying tissues. With higher dosage the exudate was 
seen to extend between the pigment epithelium and the sensory epithelium. The 
rods and cones dissolved. the inner nuclear layer disappeared and scattering of 
pigment occurred. 
Experiments with Septojod in rabbits. performed by SALLMANN in 1933. showed 
which constituent of this preparation has the retinotoxic action. Pregfs solution 
contains Nal, NaO!, NaHCO,, NaCl and free 1,. It was found that NaOI 
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(sodium hypoiodite) produced the same histological changes in rabbits as those 
described by RIEHM. SALLMANN also found that sodium hypochlorite and sodium 
hypobromite. although they could not be injected intravenously in the same 
quantities as sodium hypoiodite because of the rapid damage they cause to the 
vessel walL in smaller quantities also caused damage to the neural epithelium. 
In animal experiments destruction of the retina was obtained with sodium 
iodate (SORSBY, 1941). sodium iodoacetate (NOELL. 1952 & 1953) and sodium 
bromoacetate(LUCAS. NEWHOUSE & DAVEY. 1957). NOELL included an ERG inves-
tigation in his study: he found that the ERG disappeared directly and completely 
after the injection of iodoacetate in monkeys. rabbits and rats. 
Retinotoxic effects of phenothiazines 
N.P. 207 
In 1956 VERREY described the first ocular complications resulting from the use 
of a phenothiazine derivative. The preparation concerned was N.P. 207 (San-
doz). which had been distributed in small quantities to a few clinics for investi-
gation. 
The first complaints reported were disturbances in adaptation. In the fundus. 
if the total dose had been more than 30 gm., a severe retinopathy was seen. With 
a total dose of between 20 and 30 gm. three patients showed marked migration 
of pigment and in five cases the pigmentation was slightly abnormal. One 
patient in the group which had received less than 20 gm. showed marked pig-
ment anomalies. the other patients in this group showed slight anomalies or had 
a normal retina. 
In the slight cases the retina sometimes had the appearance of a pepper-and-
salt fundus. Using the fundus contact glass the pigmentations were seen to be in 
and under the deep layers of the retina. Further particulars about this investiga-
tion and its results were not given. 
In the subsequent discussion RI:t-.'TELEN reported also having found pigment 
anomalies in twenty-four of a group of sixty-two patients treated with N. P. 207. 
In fifteen cases a more extensive examination was possible. Dark adaptation was 
disturbed in all cases to a greater or lesser degree. A few patients had visual 
field defects and disturbances in colour vision. The visual acuity was unaffected. 
The fundus picture did not improve after the treatment was stopped, but 
improvement was seen in the dark adaptation and the visual field. 
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These findings led RINTELEN to examine patients who were being treated with 
chlorpromazine. He found no abnormalities in the fundus and the dark adapta-
tion and visual fields were also normal. 
In the further dis::ussion on VERREY's report HElM stated that. in 90% of a 
group of 120 patients treated with N. P. 207. he had seen peripapillary oedema 
which later became finely pigmented. The duration of the treatment varied from 
two to six months and the dosage was 100-500 mg. per day. 
RINTELEN, HOTZ and WAGNER reported in 1957 the complete functional recov-
ery of the fifteen patients described above. The appearance of the fundus. 
however, was not changed. 
In rabbits, rats. guinea pigs and dogs no pigmentary changes in the fundus 
were seen after giving N. P. 207. WAGNER had already come to this conclusion 
in 1956. when he reported that N. P. 207 had no effect on the retina of animals. 
MEIER-RUGE's investigations on cats. however. have shown that this conclusion 
was not justified. 
The first colour photographs of the retinopathy caused by N. P. 207 were 
made by GOAR & FLETCHER in 1957. Of 34 patients who had been treated. 28 had 
abnormal fundi. The patients" first complaints were deterioration of vision. 
night blindness and disturbed colour vision. 
Eight patients had severe loss of vision(~ 1/10). marked visual field defects 
and extensive migration of pigment in the fundus. After the treatment had been 
stopped six patients regained reasonable sight. although the visual fields remained 
restricted: two. however. remained blind. 
Four patients had less marked signs of retinopathy: in these cases. the resto-
ration of function was nearly complete. 
Sixteen patients had slight anomalies: blurred vision. some restriction of the 
visual field and slight pigment changes in the fundus. In this group recovery was 
complete after the therapy was stopped. 
The daily dose given to these patients varied from 200---2.800 mg .. the total 
dose from 900-56.000 mg. The duration of the treatment is not mentioned. 
In the early stages of the condition GOAR & FLETCHER saw hyperaemia of the 
optic disc and swelling of the arteries and veins. Within two weeks patches of 
pigment had appeared halfway between the disc and the equator. 
Two patients from the most serious group were submitted to an extensive 
examination by BURIAN & FLETCHER (1958). The first patient. a 19-year-old 
woman. had first been treated with chlorpromazine without result: the amount 
of this drug she had been given was not reported. She was then treated for a 
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period of 61/1 weeks with 42~300 mg. N. P. 207. She showed the complete patho-
logical picture described above. 
The second patient, a 31-year-old woman, also failed to react to chlorprom-
azine~ the amount she had taken was again not mentioned. She was then given 
N. P. 207 for nine weeks~ the total dose was 45,900 mg. She also presented the 
<:omplete range of abnormalities as described above. 
The visual field, examined with the Goldmann perimeter, was found to be 
severely restricted using a sma11 white object or a larger red or blue object. 
Dark adaptation, examined with the Goldmann-Weekers adaptometer, was 
seriously disturbed, the function of both the rods and the cones was affected. 
The curves obtained from N. P. 207 patients resembled those of patients with 
retinitis pigmentosa, except that the rod system was less severely affected. 
The function of the rods and cones, as indicated by the ERG. was severely 
.disturbed but not completely lost. The ERG of the first patient resembled that 
seen in congenital hemeralopia: photopic x-wave present. scotopic b~wave 
usually absent~ however. after prolonged dark adaptation. a trace ofthe b-wave 
was seen with orange and blue light stimuli. 
In the second patient no photopic x-wave was seen, only a negative deflection. 
After an hour's dark adaptation intense red light flashes, as selective stimulus 
for the cone system. produced a response without an x-wave. Blue light, a more 
or less selective stimulus for the scotopic system, and white light stimuli gave 
rise to a b-wave of moderate amplitude. 
These results of the administration of N. P. 207led to its immediate removal 
from the market and it has subsequently only been used for animal experiments_ 
In these publications mention is made several times of the variability of the 
symptoms in patients who had received approximately the same dose of N. P. 
207. It is important to note that these patients had previously taken phenothia-
zine preparations. usually in the form of chlorpromazine. The daily dose. total 
dose and duration of the chlorpromazine therapy are not mentioned in any of 
the publications. Perhaps these particulars would give an explanation of the 
varying degrees of retinopathy found in patients treated with N. P. 207. 
Thior;da:::ine (Melleril) 
WEEKLEY, POITS. REBOTON & MAY described in 1960 severe retinopathy in four 
patients from a group of 29 who were treated with large doses of thioridazine 
(Melleril). The total dosage given to these 29 patients varied from 1.2 gm. to 
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101.1 gm.; the duration of treatment varied from 4 to 181 days; the largest daily 
dose was 4 gm. 
This phenothiazine preparation is closely allied toN. P. 207, and likeN. P. 
207 fails to produce the undesirable side-effects of chlorpromazine. such as 
extra~pyramidal hyperkinesia, allergic reactions, dysfunctions of the liver and 
orthostatic hypotension (MAY, SELYMES, WEEKLEY & POTTS. 1960). 
Two of the four patients with retinopathy had severe Joss of vision as the 
result of pigmentations in the macular area; these had taken a total dose of 
thioridazine of 101 gm. and 100.2 gm. respectively. The other two patients. 
with a total dose of 98 gm. and 85.4 gm. respectively, showed no deterioration 
of vision. 
In one patient a haemorrhage was seen near a retinal vessel. In the other pa~ 
tients no anomalies of the optic disc or blood vessels were seen. 
Examination with monochromatic light showed that the pigmentations were 
situated in the deep layers of the retina. 
An ERG was made from two patients on the 75th and 89th days after the 
start of the therapy. No response to light flashes could be seen after five or ten 
minutes of dark adaptation. The ERG was again recorded on the 327th day 
after the start of the therapy, the thioridazine administration having been 
stopped in the meantime. An ERG response was now obtained, but its ampli~ 
tude diminished rapidly after a few flashes and did not recover within an hour. 
Investigation of the visual fields and dark adaptation yielded quite unreliable 
results owing to the patients' psychological condition. 
MAY, SELYMES, WEEKLEY & POTTS Suggest 1600 mg. thioridazine per day as a 
safe therapeutic dose and 800 mg. per day as a safe maintenance dose. 
MORRISON in 1960 reported a 17-year~old patient with disturbed dark adapt-
ation after taking thioridazine. 30 gm. had been taken over a period of 2 Y2 
months: for a period of 12 days the patient had been taking 1.200 mg. per day. 
The results of eye examination were negative, further details of the examination 
are not given. When the therapy was stopped the complaints disappeared. 
SCOTT in 1963 described a 19-year-old male schizophrenic with extensive 
retinopathy following treatment with thioridazine. During a period of hospitali-
zation he was given 50 gm. of thioridazine in three months. The average daily 
dose was 550 mg. Nine months later the patient was readmitted to hospital: in 
two months· time he was given a total dose of 118.5 gm. thioridazine; the average 
daily dose was 1.975 mg. Deterioration of vision and visual field defects devel-
oped. Three weeks after the therapy had been stopped scorr saw pigmentations 
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in the fundus, central and peripheral but not at the extreme periphery. Three 
weeks later dark adaptation was disturbed. Six months after stopping treatment 
the vision and retinal pigmentations were unchanged. The critical flicker 
frequency (CFF) was normal in the central area up to 20° from the centre~ 
peripherally it was markedly abnormal. The dark adaptation curve registered 
the function of the cone system only. The ERG, however, was normal. Later the 
vision improved considerably, although scotopic vision remained poor. The 
pigmentations remained. 
APPELBAUM in 1963 examined 77 patients who were being treated with thiori-
dazine. The daily dosage varied from 100 to 600 mg. and the duration of the 
treatment from 1 to 14 months. The examination consisted of funduscopy 
under narcosis. No pigmentary anomalies of the retina were seen. 
CONNELL et al. in 1964 described a 37-year-old woman with retinopathy after 
taking 40 gm. thioridazine. The largest daily dose had been 1.2 gm., the 
treatment had been continued for forty days. She had also been given 100 mg. 
imipramine and 5 mg. benztropine methanesulphonate per day. The visual 
acuity had deteriorated and the visual fields were markedly reduced. Visible 
changes in the fundus did not appear until later. Colour vision was normal. The 
ERG showed abnormalities of both the photopic and the scotopic systems. The 
dark adaptation curve also indicated reduced function of the rods and cones. 
Vision improved after the treatment was stopped, the scotomata became smaller 
but the retinopathy remained. 
FINN in 1964 reported on a 23-year-old patient suffering from an acute schizo-
phrenic psychosis who developed a retinopathy following thioridazine 
treatment. The total dose taken was 50-60 gm. over a period of 56 days; the 
largest daily dose was 1.4 gm. The visual fields were concentrica11y severely 
reduced. Vision in the dark was poor but dark adaptation curves were not made. 
The visual acuity was poor. After the treatment was stopped the visual acuity 
recovered and the scotomata became smaller. The abnormal pigmentation in the 
fundus remained. 
HAGOPIAN et al. in 1966 examined 164 patients who were being treated with 
thioridazine. Eight of these patients were taking a daily dose of more than 
1.800 mg.; five of these had deterioration of vision and extensive migration of 
pigment in the fundus. Before the thioridazine treatment these patients had taken 
drugs and the authors could not exclude the possibility of an additive or cumu-
lative effect. When the thioridazine was discontinued vision improved but the 
pigmentations remained. 
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Chlorpromazine (Largactil) 
BAUMANN in 1957 reported on 35 schizophrenics who were being treated with 
chlorpromazine. Their ages varied from 31 to 65 years. the duration of the treat-
ment from 6 months to 211z years and the total amount of chlorpromazine they 
had taken from 25 to 248 gm. 
The Goldmann-Weekers adaptometer was used to investigate the dark 
adaptation. The visual fields were determined with the Goldmann perimeter. 
Colour vision was examined with the Ishihara pseudo-isochromatic plates. The 
fundus was carefully studied by direct and indirect ophthalmoscopy in homa-
tropine mydriasis. No abnormalities were found in 24 cases. 
The results of the examination of the other 11 patients were reported in more 
detail. Nine patients had slightly abnormal visual fields and dark adaptation. 
which could be explained by opacities in the media or the patients" mental 
condition. It was possible that two patients had slight retinopathy. consisting 
Df exaggerated pigment mottling. 
According to this author. chlorpromazine in normal dosage does not cause 
retinal damage; the dosage. however, is not mentioned. 
BUSCH. BUSCH & LEHMANN in 1963 found no ocular abnormalities in 363 pa-
tients who were being treated with chlorpromazine and promethazine. The 
investigation was limited to the determination of the visual acuity and refraction 
and to funduscopy: whether the latter was performed in mydriasis is not 
mentioned. The daily dosage varied from 50 to more than 250 mg. of the pheno-
thiazine preparation. the duration of the treatment was from two months to 
more than three years. The total dose taken by each patient was not reported. 
SIDDALL (1965) described anomalies of the conjunctiva. cornea. lens and retina 
in fifty patients treated with chlorpromazine. A dark film over the retina was 
seen in ne3.rly all C3Ses. In eleven cases there was definite granularity: in four 
cases there was clumping of pigment: one of these clearly showed migration of 
pigment in the fundus. Two of the patients with retinal anomalies had a reduced 
visual field and one poor vision - this was partly due to opacities in the cornea 
and lens. The author expects ocular complications to occur after about twenty 
months" tre3.tment with a daily dose of 800 mg. chlorpromazine. 
RAB. ALAM & SADEQUZZAMAN (1969) described atrophy of the optic nerve and 
retinopathy in both eyes of a 27-year-old man following chlorpromazine treat-
ment. The daily dosage had been 500 mg. for eleven weeks and 150 mg. for one 
week. 
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Other oculo-toxic effects of phenothiazine derivatives 
In 1963 BOCK & SWAIN examined 27 patients who, for two years or longer, had 
been taking a minimum daily dose of 200 mg. chlorpromazine. They reported 
incidentally in one patient ·fine, powdery white spots on the anterior {lens) 
capsule in the central pupillary area·. a phenomenon which was to be reported 
very frequently in later publications. 
In two patients they found that the intra-ocular pressure was raised. Their 
own observation on 1000 unselected patients was that chronic glaucoma is 
found in 1.9 %. In one case they also found marked migration of pigment in the 
fundus. although this patient. who had been given a daily dose of 50 mg. 
chlorpromazine for three years, did not fulfil their criteria for dosage. The au-
thors emphasized the ·atropine-like· action of chlorpromazine and the impor-
tance of measuring the ocular pressure of patients who are being treated with 
this preparation. 
BIERENT, however, in 1954, and SANA (1958) found that chlorpromazine 
lowered the intra-ocular pressure in acute glaucoma. Lowering of the pressure 
was also obtained by PAUL & LEOPOLD (1956) in cats and by CONSTANT & BECKER 
(1956) and RAMos. CALDEIRA & RAMOS (1967) in rabbits by means of intravenous 
or intracisternal injection of this preparation. 
RAMOS. GIESBRECHT. CALDEIRA & RAMOS (1969) found a decrease in the chloride 
and sodium concentration of the aqueous in rabbits treated with chlorprom-
azine. The potassium content of the aqueous was not significantly decreased. 
although there was a significant lowering of the potassium content of the serum. 
The authors consider that the effect of chlorpromazine in lowering the ocular 
pressure is due to the action of the drug on the central nervous system. 
In 1964 GREINER & BERRY described slate-blue discoloration of the skin. where 
it was exposed to sunlight, in female patients who were being given an average 
daily dose of500-1,500 mg. chlorpromazine (confirmation of PERROT's observa-
tion in 1962). The cause of the discoloration was accumulation of melanin in the 
superficial layers of the dermis. especially around the blood vessels. Examination 
of the eyes of these patients revealed brown discoloration of the sclera 
and yellowish-white granules in the stroma of the cornea. in the central area. 
The authors also saw yellowish-white granules in the form of a star centrally 
situated on the anterior surface of the lens. Abnormalities of the retina were not 
reported. 
In the same year GREINER & NICOLSON reported the unexpected death of twelve 
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young adults, who had been receiving prolonged chlorpromazine treatment. 
Five of them showed skin discoloration: two of these had complained of deterio-
ration of vision but the cause of this is not mentioned. On autopsy melanin was 
found in the macrophages of the dermis, in the reticulo-endothelial system. and 
in the parenchyma cells of the liver, kidneys and lungs. The eyes of these pa-
tients were not examined. The authors ascribe the melanosis to accelerated 
destruction of adrenalin and nor-adrenalin and reduced production of melato-
nin. 'Melanin is formed in the cytoplasm of melanocytes by oxidation of the 
amino-acid tyrosine in the presence of the enzyme tyrosinase. Its production is 
under hormonal an.:l neural control. The amount of pigment in a particular 
melanocyte is determined by the balance of darkening and lightening factors. 
The most important darkening factors are alpha and beta melanocyte stimulating 
hormones (MSH), androgen. oestrogen, and thyroid extract. Lightening factors 
include: adrenalin, nor-adrenalin, serotonin and melatonin, which is present in 
the pineal body and in peripheral nerves. Phenothiazines decrease the release of 
adrenalin and nor-adrenalin. There will be a relative excess of MSH, with over-
production of melanin. Furthermore. by inhibiting sympathetic nervous system 
function, phenothiazines may impair melatonin production·. 
In a later article GREil\.'ER, NICOLSON & BAKER (1964) described a possible 
treatment for this melanosis. The enzyme tyrosinase plays an important r6le in 
the formation of melanin. Tyrosinase contains copper. If a chelating agent is 
given which combines with the copper. this reduces the activity of the tyrosinase. 
The authors used d-penicillamine (.~. ~-dimethylcystine) as chelating agent for 
copper: 
CH3 I 
CH - C - CH - COOH 3 I I 
SH NH 2 \., / +--chelation 
c~ 
This is a break~dovm product of penicillin and is used in hepatolenticular 
degeneration (Wilson's disease), siderosis of the eye, etc. 
Six patients were treated with d~penicillamine: they were also instructed to 
stay in the dark or wear sun~glasses, measures which should stimulate the pro-
duction of melatonin. In addition. four of the six patients were given no more 
phenothiazines. These four patients showed a remarkable loss of colour after 
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four weeks. Of the two patients who had continued with phenothiazine treatment 
while taking penicillamine and remaining in the dark, one showed a slight loss of 
colour and the other was unchanged. As controls two patients who were given 
neither penicillamine nor chlorpromazine remained for four weeks in the dark: 
these patients showed some loss of colour, but to a lesser extent than the first 
four patients. 
ZELICKSON & ZELLER (1964) described eight patients with discoloration of the 
skin. where it was exposed to the sunlight, following treatment with phenothia-
zine derivatives. In one case the discoloration was also seen behind the patient's 
glasses. This led the authors to conclude that light above the wave length of 
3200 A plays a rOle in the discoloration. Three of these eight patients had in-
creased pigmentation, and also areas of depigmentation, in the fundus. 
BAN & LEHMANN (1965) found typical skin pigmentation in ten women and 
five men who had been taking chlorpromazine. The daily do£e varied from 300 
to 1,000 mg.: some patients were also being given other phenothiazine prepara-
tions at the same time. The duration of treatment varied from two to nine years. 
Thirteen of these patients were found to be photosensitive on exposure to ultra-
violet light for one minute. Some other patients who had been taking other 
phenothiazine preparations were also found to be photosensitive. 
Anomalies of the conjunctiva, cornea and lens typical for chlorpromazine 
were found in fourteen of the :fifteen patients. Ten patients who had been taking 
other phenothiazine preparations but no chlorpromazine showed anomalies of 
the lens and cornea in eight cases but no conjunctival pigmentations. There was 
a correlation between the severity of the ocular complications and the dosage 
of the phenothiazines. The retinae of these patients were probably norm~l, but 
this is not specifically stated. 
MARGOLIS & GOBLE in 1965 found lens anomalies in eight of a group of thirty-
one patients who were being treated mainly with trifluoperazine. With the slit-
lamp they saw 'dust-like. red-brown, granular particles in the anterior lens 
cortex. near the lens capsule, dispersed in stellate or occasionally in a dendritic 
fashion·. The intra-ocular pressure. visual acuity and visual :fields were normaL 
Abnormal pigmentation in the retina was not seen. In their conclusion. they 
make the suggestion, seeing that these patients had been taking various pheno-
thiazine derivatives. that all phenothiazine preparations may give rise to ocular 
complications. 
BARSA, NEWTON & SAUNDERS (1965) examined a group of 658 female patients 
of whom 145 had opacities in the lens as the result of phenothiazine treatment. 
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The patients were divided into four groups according to the density of the opaci-
ties. In the group with the densest lens opacities corneal opacities were also al-
ways present; this was the case in 33 cases. The percentage of patients with 
raised intra-ocular pressure was not above normal. No pigmentary changes were 
seen in the fundus. The authors urge the importance of regular control of the 
eyes of patients who are being treated with phenothiazine preparations. a 
suggestion which is also supported by POTTS & MEIER-RUG£. 
SANDVIG (1965) examined twenty-seven patients who were being treated with 
-chlorpromazine and found in twenty-three cases typical anomalies in the lens and 
'('Orne3.. Of these twenty-three. twenty were female and three male. Seventeen 
patients could be examined ophthalmoscopically: the fundi were normal. The 
average daily dose varied from 400 to 2.400 mg. 
VVETIERHOLM, SNOW & WINTER in 1965 examined 384 male patients who had 
been receiving chlorpromazine treatment. The average daily dose varied from 
300 to 1.600 mg .• the total dosage from 1.000 to 2.000 gm. In 125 cases. 32.5 %. 
1he authors found typical opacities in the cornea and lens. One patient had a 
red-green colour defect. Three showed ·a light pigmentary mottling of the fundus 
due to increased choroidal pigmentation·. In five cases an ERG could be made: 
it was normal in all cases. 
CAIRNS. CAPOORE & GREGORY in 1965 described four cases of diffuse opacities 
in the stroma of the cornea, associated with lens opacities, following the admini-
stration of chlorpromazine. The fundus and the optic nerve were normal. 
MCCLANAHAN et al. (1966) described eleven patients with conjunctival discolora-
tion and lens pigmentations resulting from chlorpromazine treatment and one 
patient with retinal anomalies caused by thioridazine. 
JOHNSON & BUFFALOE in 1966 described epithelial lesions of the cornea. These 
had also been reported by SIDDALL (1965). The keratopathy was limited to the 
lower half of the cornea and consisted of white, grey and brown lines. The 
average daily dose of chlorpromazine given to these patients was 2.000 mg. 
DENCKER & ENOKSSON in 1966 reported fourteen patients with skin pigmenta-
tions following chlorpromazine treatment: ten of these also had typical corneal 
and lens anomalies. No mention was made of the retina. 
In 1966. EDLER examined 261 patients who had been receiving phenothiazine 
therapy. Fifty-two patients had anomalies of the lens and cornea and fourteen 
had a pepper-and-salt fundus. In 153 cases the author saw brown deposits of 
pigment on the anterior surface of the iris. Naevi. sometimes resembling melano-
mata, were also seen. In one case the corneal precipitates disappeared with local 
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"Cortisone treatment. but a cataract developed. probably as a result of the corti-
sone eye-drops. When the drops were stopped the precipitates reappeared. When 
both the chlorpromazine and the eye-drops were stopped the corneal precipitates 
disappeared and the cataract became less dense. A rise in intra-ocular pressure 
was not found. 
Articles published by MATHALONE in 1965, 1966 and 1967 describe the exami-
nation of 462 patients who were being treated with chlorpromazine. He found a 
-correlation between corneal and lens opacities on the one hand and the duration 
of the therapy and the dosage of the drug on the other hand. The intra~ocular 
pressure was not raised. An EOG was made in thirteen cases: the LP/DT ratio 
was low but. according to the author. still within the limits of normal. In 
two cases pigmentations were seen in the fundus. Ten patients were treated 
with d-penicillamine for eight months. in eight cases the chlorpromazine treat-
ment was also stopped. Of these eight. two showed improvement in the lens 
condition and two in the keratopathy. As the results were not spectacular the 
penicillamine treatment \vas stopped. 
CAMERON (1967) considered that ultra-violet light of wave-length greater than 
3.200 A is responsible for the pigmentation of the skin. cornea and lens. In the 
-opinion of the author.light from the sky is focused onto the anterior part of the 
eye, and ultraviolet light mainly onto the anterior lens capsule. so that lens 
changes may be expected to be a sensitive sign of phenothiazine intoxication. 
HOFMAN (1967) described 6 female patients with blue discoloration of the face. 
Opacities in the cornea and lens were found in 4 patients. one of whom also had 
brown pigmentations in the sclera in the palpebral fissure. 
KASSMAN & WETTERBERG (1967) found lens opacities in eleven patients who had 
each taken a total dose of more than 600 gm. laevomepromazine. The urine of 
these patients contained a porphobilinogen-like substance. The authors are 
going to investigate the significance of this further. 
NO URI & CUENDET (1968) examined 225 patients and found lens opacities in 54 
c1ses (24 %) and corneal opacities in 12 cases (5 %). The patients had teen main-
ly treated with chlorpromazine: the daily dose varied from 25 to 300 mg. and 
the total dose from 300 to 1.530 gm. In one case retinopathy was seen. 
Animal experiments 
In 1966 MEIER-RUGE & CERLETTI obtained in cats who were being treated with 
piperidylchlorophenothiazine (N. P. 207). pigment changes in the fundus. which 
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were similar to those produced in man by this preparation. Initially finely-
speckled greyish-brown pigmentations appear. which become coarser if the admi-
nistration of the drug is continued. The pigmentation is caused by accumulation 
oflipoids in the pigment epithelium; the lipoid comes from the distal segment of 
rods which have been destroyed. The authors established by means of histolo-
gical staining that reduction of adenosine triphosphatase precedes the destruc-
tion of the distal rod segment. The activity of lactic dehydrogenase. alkaline 
phosphatase and phosphomonesterase I is also reduced. Acid hydrogenase is 
unaffected: 'this enzyme seems to be retained as long as the visual cell survives. 
so that the distal rod segment is able to regenerate". 
MCDONALD. SNELL & LERNER (1967) administered chlorpromazine to guinea 
pigs and irradiated them with ultraviolet light. They observed small white dots 
in the anterior subcapsular area and also in the posterior cortex of the lens. The 
opacities resembled those seen in man during chlorpromazine therapy. 
BEEHLER. ROBERTS & SALEM (1968) obtained an increased frequency of retinal 
detachments in dogs living in a high concentration of oxygen. if they were given 
chloroquine or phenothiazine derivatives. They ascribed this to degenerative 
changes in the retina caused by these drugs. 
MEIER-RUGE. in his excellent monograph (1967) describes selective absorption 
of the phenothiazines on the melanin of the choroid. He therefore concludes 
that every phenothiazine derivative is more or less toxic for the retina. POTIS also 
comes to the same conclusion. 
To summarize. from the literature it appears that phenothiazine derivatives, 
given in high dosage and for long periods of time, can give rise to: 
a. discoloration of the skin where it is exposed to the sunlight~ 
b. discoloration of the conjunctiva: 
c. discoloration of the sclera: 
d. opacities in the cornea (epithelium. stroma. endothelium): 
e. opacities of the lens near the anterior capsule; 
f. retinopathy in the form of: 
1. migration of pigment and 
2. disorders of retinal function. both subjective (visual acuity. visual fields. 
dark adaptation, colour vision) and objective (ERG, EOG). 
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PRESENT STUDY 
1. Material 
The patient material for this study came from two psychiatric hospitals: Delta 
Ziekenhuis in Poortugaal (Rotterdam) and Stichting Rosenburg in The Hague. 
Male and female patients~ who were being treated with phenothiazine prepa-
rations. were examined. No selection was made on the basis of duration of 
treatment. size of daily dose or nature of the phenothiazine preparation being 
taken. Usually various derivatives had been prescribed in varying dosages in the 
course of the treatment. sometime3 with a period without medication between. 
On p. 32 further particulars are given about the prescribed preparations. 
Our original intention was to restrict the study to patients under 45 years of 
age, in order to avoid confusion between retinal changes caused by pheno-
thiazine preparations and those due to arteriosclerosis. When it appeared. 
however. that this would make the number of patients examined in Stichting 
Rosenburg too small. it was decided to include patients above 45 years of age in 
the study. Furthermore. the objections to this carried less weight, as the expe-
rience gained in the recognition of the retinal changes caused by phenothiazine 
treatment enabled us to distinguish them more easily from other types of fundus 
anomaly. 
TABLE I 
Age and sex distribution of 541 patients 
Males No. % Females No. % 
< 45 years 160 29.6 < 45 years 129 23.8 
> 45 years 100 18.5 > 45 years 152 28.1 
Total 260 48.1 Total 281 51.9 
The whole study included 561 patients. Twenty of these were found to have 
abnormal fundi due to other causes than phenothiazine therapy and were 
excluded from the study. The age and sex distribution of the remaining 541 
patients is shown in Table I. 
2. Method 
As the examination of561 patients by one man would have taken too much time, 
the help of The Netherlands General Association for Prevention of Blindness was 
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called in. The Association allowed its Rotterdam field-workers to work on this 
study for two years. These field-workers are doctors studying to be ophthal-
mologists at one of the Dutch Eye Hospitals. who are lent to the Association for 
Prevention of Blindness for a period of six months for research work. In this 
way. examination of the patients in Delta Ziekenhuis was undertaken by the 
author's colleagues Alkemade*. Craandijk. Rozemeijer and Miss Mertens. The 
examination of the patients in Stichting Rosenburg was performed by the author. 
The medical staffs of the Eye Hospital in Rotterdam. Delta Ziekenhuis and 
Stichting Rosenburg offered all possible assistance. and the nursing staffs of the 
last two hospitals were extremely helpful. I am very grateful to all these people. 
Discussions between the field-workers and the author took place regularly 
in order to ensure that the interpretation of the results obtained should be 
uniform. Also patients were often examined together. 
A scheme for a standard examination was drawn up, which was applied as far 
as possible to all patients. Considering their mental state. however. it was to be 
expected that in many cases it would not be possible to obtain reliable results 
fro.m all the tests. 
The examination was carried out in two or three sessions and covered the 
following points: 
I. case history. with special emphasis on the presence or absence of photo-
sensibility: 
2. external examination: inspection of the eyes, eyelids and skin and the colour-
ing of the patient (dark or blonde): 
3. slit-lamp examination, where possible (Haag Streit. magnification 25 x): 
4. measurement of the intra-ocular pressure (where possible) by means of the 
Schi6tz tonometer or the Goldmann applanation tonometer: 
5. funduscopy in mydriasis, by both the direct and the indirect method: rapid 
mydriasis of short duration was obtained by means of Mydriaticum (Labora-
toires Chibret. formula: Acid. tropic. N-ethyl-N-(;r-picolyl)-amid. 5 mg~_ 
Natr. sulfuric.-phenylhydrargyr. nitric. 0.01 mg: aqua ad 1 ml): 
6. investigation of the retinal function: 
a. visual acuity, with and without correction: 
* The patients described by ALKEMADE (J 966. 1968) arc included in this study. 
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b. colour vision, by means of the Ishihara pseudo-isochromatic plates and 
the Hardy-Rand-Rittler test: 
c. an electro-oculogram (EOG) was made on selected cases; the selection was 
dependent upon whether the patient was calm and cooperative and 
whether he could shift his gaze adequately from right to left. 
The method of obtaining and recording the EOG was that described by 
HENKES et al. in 1968. In electro-oculography the standing corneo-fundus poten-
tial is measured indirectly by means of electrodes which are placed alongside the 
c 
0 b 
Fig. 1 
(A) Principle of recording of standing potential based upon alterations in the electric 
field resulting from eye movements. 
(B) Resulting changes in potential between the electrodes. 
(C) The upper trace of the original graphs shows movements of the right eye: the lower 
one of the left eye. The amplitude of the initial vertical excursions is a measure of 
the height of the standing potential. 
(a) after 12 minutes dark adaptation: (b) S minutes after re-illuminating the retina_ 
Calibration bars: 500 microvolts. 500 msec. (after ARDEN. BARRADA & KELSEY. 1962) 
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external and internal canthi of both eyes. When the eyes are moved a change in 
potential between the two electrodes can be recorded (see Fig. I). This change 
in potential is small in dark adaptation and larger in light adaptation (light 
peakjdark trough- LP/DT- ratio). 
The EOG gives information about the quality of the choriocapillaris. Bruch ·s 
membrane. the pigment epithelium and the rods and cones of the retina (ARDEN. 
1962). The lower limit of normal for the LP/DT ratio was taken as 165%. as 
suggested by HENKES el al. (1968) and KELSEY (1967). 
As was to be expected. in many cases either it was impossible to make an 
EOG altogether or the results were unreliable. In the majority of cases it was 
also impossible to investigate the visual fields or dark adaptation. 
The psychiatrist's diagnosis was noted in all cases. 
For all patients careful note was taken of the drugs which had been given. 
the length of time they had been taken and the dosage which had been pre-
scribed. From these data the total dosage and the average daily dose of the prepa-
rations were calculated for each patient. Particulars of therapeutic measures 
taken during earlier periods of hospitalization in other hospitals were unfortu-
nately difficult to obtain and not very exact. 
The phenothiazine preparations which had been taken by the patients in-
-cluded in this study were: promazine. chlorpromazine, trifluopromazine. 
laevo-mepromazine. promethazine, mepazine. thioridazine. propericiazine. 
perazine. prochlorperazine. trifluoperazine. thioproperazine, perphenazine and 
thiopropazate. 
OBSERVATIONS 
Skin & Eyelids 
Slate-blue discoloration of the exposed skin was seen and in these cases the 
eyelids were also discoloured. Discoloration was not seen in folds of the skin 
into which the sunlight could not penetrate. 
Conjunctiva 
Brown pigmented stains were seen in the conjunctiva. They had a granular 
appearance and were situated in the palpebral fissure usually near the limbus 
corneae. 
Central phenothiazine retinopathy 
Plate I 
Plate 3 
Plate 5 
Plate I 
Normal pattern of retinal pigmentation 
Plate 2 
Star-shaped opacity on lens 
Plates 3 & 4 
Phenothiazine retinopathy (central); right and left eyes of one patient 
Plate 5 
Central retinopathy photographed with orthochromatic film 
Plate 6 
Same fundus photographed with panchromatic film 
Plate2 
P1atc4 
Plate 6 
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Cornea 
Fine yellowish-white granules were seen in the deeper layers of the corneal 
stroma, in Descemet"s membrane and in or on the endothelium. They resembled 
very fine pollen and were always centrally situated, never at the limbus. 
Lens 
'Pollen deposits" were also found on the anterior surface of the lens and under 
the surface. Occasionally the lens opacities were star-shaped. The yellowish-
white granules were again found in the centre or sometimes just below the centre. 
Retina 
For the sake of clarity a description of the normal retina (DUKE-ELDER: BALLAN-
TYNE & MICHAELSON) is given before proceeding to the anomalies found during 
this study. 
The normal retina is red in colour when examined with white light. The red 
colour is produced by the light reflected from the choroid and varies with the 
degree of pigmentation of the choroid. The chorojdal pigmentation corresponds 
with the generalized degree of pigmentation of the individual. 
The choroidal pigment can be seen as dark polygonal areas between the 
choroidal vessels. which. however. are usually not visible. These areas are very 
pronounced in dark individuals. the so-called tigroid or tesselated fundus. 
The retinal pigment has practically no influence on the colour of the fundus. 
The amount of pigment in the retinal epithelium shows very little individual 
variation. except in the case of albinos. If the pigment is deficient the choroidal 
vessels can be seen against the background of the underlying sclera. 
The pigment epithelium of the retina appears as a fine granulation over the 
fundus. At and around the macula this is difficult to see because of its very regu-
lar distribution. At the periphery. near the ora serrata. the granulations are 
coarser and less regular and can be more e3Sily seen. 
According to HOGAN & ZIMMERMAN the pigment epithelium consists of a layer 
of regularly arranged hexagonal cells containing rod-shaped melanin granules 
in their inner part. These granules become rounded in the process of aging. 
In this study we found that phenothiazine derivatives produced coarsening of 
the retinal pigmentation and patches of depigmentation. Where the coarsening 
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was discernible but not marked, the term "slight retinopathy" was used; where it 
was very marked and the choroidal pigmentation was also affected. the condition 
was called ·severe retinopathy"*. The foveolar reflex was usually absent, even in 
the slight cases. The pigmentations were not particularly marked at the foveola. 
In the majority of cases the whole fundus was equally affected by the pigmentary 
changes: this was described as ·central and peripheral' localization of the retino-
pathy. In a very much smaller number of cases the coarsening of the pigmenta-
tion was only seen at the periphery or only in the central area: this was described 
as either "peripheral' or ·centrar retinopathy. The pigmentations always had a 
regular pattern. A depigmented area round the macula, like the "bull's eye' seen 
in chloroquine retinopathy. was not found. The optic disc and blood vessels 
were normal. 
In the group of patients above the age of forty-five. it was sometimes difficult 
to distinguish the pigmentary changes in the fundus due to arteriolosclerosis 
from those which are seen in phenothiazine retinopathy. In our opinion. 
however, there are differences: the pigmentations which occur as the result of 
arteriolosclerosis, particularly of the choroid. are coarser and more irregularly 
distributed and are darker in colour. According to PILLAT (1950) and BALLAN-
TYNE & MICHAELSON (1962) arteriosclerotic pigmentary changes occur much 
more frequently at the periphery than at the macula. If there are clear signs of 
arteriolosclerosis to be seen in the retinal and choroidal vessels, this can also be 
an aid to the differential diagnosis. In some older patients both arteriolosclerotic 
and phenothiazine pigmentations were present: if this was thought to be the case 
the funduscopy was performed by more than one examiner, and if no agreement 
could be reached the patient was classified as not suffering from phenothiazine 
retinopathy. 
Electro-oculogram 
In an appreciable percentage of cases the EOG values were too low. These 
findings will be further discussed on p. 48. 
RESULTS 
The patient material was too large to allow straightforward evaluation of the 
results obtained. so assistance was asked and obtained from the Statistical 
* for definition of retinopathy see p. 52. 
central 
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Effects of phenothiazines on the eye 
conjunctiva & cornea 
lens 
Retinopathy 
peripheral 
Fig. 2 
n \ 
·. I \·\~) 
central and peripher:al 
Schematic representation of the toxic effects of phenothiazines on the eye. 
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Bureau ABW-TNO. With their co-operation a code system was devised, which 
enabled us to deal with all the data mechanically. All the eye conditions found 
were given code numbers. This was also the case with the drugs used, the psyw 
chiatric diagnosis. the sex and age of the patient and the hospital in which the 
examination had taken place. The duration of the treatment. the dosage of the 
preparations and the average daily dosage were also registered. The code num-
bers were transferred to punch cards and. with the help of a Hollerith machine. 
a computer and statistical calculations the following results were obtained. 
Skin pigmentation 
In five women pathological pigmentation of the face. eyelids. etc. was seen 
(0.9%). 
Photosensitivity of the skin 
In 49 cases a history of photosensitivity could be elicited, either from the patient 
himself or from others (9.1 %). 25 women and 24 men were affected. 
Cornea 
Typical corneal opacities were found in 8 patients. 7 women and one man (1.5 %). 
These opacities could only be seen on slit-lamp examination. 
Lens 
Opacities in the lens were found in 46 patients (8.5 %), 22 women and 24 men. 
Except in the most pronounced cases these were also only visible with the slit-
lamp. 
The correlation between the corneal and lens opacities and the total dose of 
phenothiazine preparations. the average daily dose and the duration of the 
treatment is given in Table II. 
Intra-ocular pressure 
It was possible to measure the intra-ocular pressure of 26 patients (52 eyes), 11 
men and 15 women. Raised pressure (25 mm. Hg) was found on the left eye of 
one man. the diagnosis was subsequently made of glaucoma simplex. 
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TABLE II 
Corneal and lens opacities 
Total dose Males Females Lens Corneal 
in grns. opacities opacities 
< 500 9 9 IS 2 
500- ],000 7 7 12 3 
1,000- 1500 6 5 12 2 
> 1500 2 2 4 
Total: 24 23 46 s 
Average daily Males Females Lens Corneal 
dose in mgs. opacities opacities 
< 100 0 2 2 0 
100- 200 6 8 13 3 
200- 300 s 6 14 
> 300 10 7 17 4 
Total: 24 23 46 8 
Duration of Males Females Lens Corneal 
therapy in opacities opacities 
months. 
< 24 I 2 0 
24-48 I 3 4 
4S- 96 II 7 IS 3 
96- 120 5 4 9 
> 120 6 s 13 3 
Total: 24 ?' 
-0 46 s 
Retina 
Retinopathy was found in 343 cases (63.4 %). In the age-group below 45 years 
160 of the 289 patients had this condition (55.3 %), above the age of 45 it was 
seen in 183 of the 252 patients (72.6 %). See Fig. 3 and Table III. 
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Fig. 3 
Age distribution of retinopathy 
With 
retinopathy 
160 
183 
343 
TABLE ill 
Without 
retinopathy 
129 
69 
198 
Total 
289 
252 
541 
% 
55.3 
72.6 
63.4 
The distribution by age and sex was as follows: 113 of the 160 men under the 
age of 45 had retinopathy (70.6%), 67 of the 100 men above the age of 45 
(67.0%). 47 of the 129 women under the age of45 (36.5%) and 116 of the 152 
women above the age of 45 (76.3 %) were also affected, see Fig. 4 and Table IV. 
234 of the patients included in the study were blonde, and of these 152 (66 %) 
had retinopathy. Of the 296 dark patients examined !82 (63 %) had retinopathy. 
Age 
< 45 
> 45 
Total 
Age 
-< 45 
> 45 
Total 
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Fig.4 
Distribution of retinopathy by age and sex 
TABLEN 
Age distribution of retinopathy 
Females 
With 
retinopathy 
47 
116 
163 
With 
retinopathy 
113 
67 
180 
Without 
retinopathy 
Males 
82 
36 
118 
Without 
retinopathy 
47 
33 
80 
Total 
129 
152 
281 
Total 
160 
100 
260 
39 
% 
36.5 
76.3 
56.4 
% 
70.6 
67.0 
68.8 
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Fig. 5 
Type and site of retinopathy 
TABLE V 
Type and site of retinopathy 
(number of patients) 
Severe Slight Total 
Peripheral 4 13 17 
Central 8 75 83 
Central and peripheral 104 139 243 
Total 116 227 343 
Type and site of retinopathy 
(percentages) 
Severe Slight Total 
Peripheral 1.2 3.8 5 
Central 2.3 21.9 24.2 
Central and peripheral 30.3 40.5 70.8 
Total 33.8 66.2 100.0 
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Subdivision of the patients with retinopathy by localization and severity of 
the retinal condition yields the following results: 
peripheral retinopathy: 
central retinopathy: 
severe. 4 patients (1.2 %) ; 
slight. 13 patients (3.8%); 
severe. 8 patients (2.3 %) ; 
slight, 75 patients (2L9 %) : 
central and peripheral retinopathy: severe, 104 patients (30.3%); 
slight, 139 patients (405%), 
Further subdivision according to the age and sex of the patient yields the 
following figures: 
Slight central and peripheral retinopathy: 
33 men of the 160 under the age of 45 = 20.6% 
30 men of the 100 above the age of 45 = 30.0% 
21 women of the 129 under the age of 45 = 16.3% 
55 women of the 152 above the age of 45 = 36.2 % 
Severe central and peripheral retinopathy: 
30 men of the 160 under the age of 45 ~ 18,8% 
26 men of the 100 above the age of 45 = 26.0% 
11 women of the 129 under the age of 45 = 8.5% 
37 women of the 152 above the age of 45 = 24.3% 
Slight central retinopathy: 
40 men of the 160 under the age of 45 = 25.0% 
7 men of the 100 above the age of 45 = 7.0% 
9 women of the 129 under the age of 45 = 7.0% 
19 women of the 152 above the age of 45 = 12.5% 
Severe central retinopathy (no percentages as figures too small): 
4 men under the age of 45 
I men above the age of 45 
2 women under the age of 45 
I woman above the age of 45 
Slight peripheral retinopathy (no percentages) 
6 men under the age of 45 
3 men above the age of 45 
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3 women under the age of 45 
I woman above the age of 45 
Severe peripheral retinopathy (no percentages): 
0 men under the age of 45 
0 men above the age of 45 
1 woman under the age of 45 
3 women above the age of 45. 
On the basis of psychiatric diagnosis the patients were distributed as follows: 
TABLE VI 
Correlation between retinopathy and psychiatric diagnosis 
Diagnosis without with Total 
retinopathy retinopathy 
Schizophrenia 87 165 252 
Hebephrenia 8 7 15 
Paraphrenia 0 5 5 
Catatonia 2 
Paranoia 10 13 23 
Alcoholic psychosis 7 8 
Degenerative psychosis 6 9 15 
Dementia paralytica 5 6 
Exogenous psychosis 3 10 13 
Epilepsy 14 12 26 
Moderate mental retardation !0 10 20 
Borderline of mental retardation 26 43 69 
Depression 10 34 44 
Mania 5 4 9 
Hysteria 3 8 II 
Neurosis 3 4 
Unknown 12 7 19 
Total 198 343 54! 
LOEHNER (1938), MCISAAC (1969), VANDERKAMP (!963) and LEA (1955) have de-
scribed a disturbance of melanogenesis in schizophrenics. As the phenothiazines 
also affect the melanogenesis. we examined our material to see if retinopathy 
was relatively more frequently seen in schizophrenics than in the other patients. 
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TABLE VII 
Retinopathy in schizophrenic group 
Diagnosis Without With Total 
retinopathy retinopathy 
Schizophrenic group 106 191 297 
Others 92 152 244 
Total 198 343 541 
Expressed in percentages, retinopathy was found in 64.3% of the patients in the 
schizophrenic group and 62.3% of the other patients. There was thus no signifi-
·cant difference in the incidence of retinopathy in the two groups. 
In order to determine the effect of the phenothiazine treatment on the inci-
dence of retinopathy the statisticians subdivided the patient material into 
groups. The relationship between the total dose of phenothiazine preparations 
taken and the retinopathy is as follows: 
TABLE VIII 
Retinopathy and total dose of phenothiazine preparations 
Total dose Retinopathy No retinopathy Total 
in grammes 
< 50 86 77 163 
50- 149 75 45 120 
150- 349 78 34 102 
350- 749 77 35 102 
> 750 47 7 54 
The percentage of retinopathy is different in the various groups: the correlation 
between the incidence of retinopathy and the total dose of phenothiazine prepa-
rations is highly significant (x2 = 21.69. P = 0.0002). See also Fig. 6. 
The relationship between the average daily dose of phenothiazine preparations 
and the retinopathy is as follows: 
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TABLE IX 
Retinopathy and average daily dose of phenothiazine preparations 
Daily dose 
inmg 
< 40 
40-99 
100- 189 
> 190 
en 200 
~ 
z 
w 
~ 
~ 
0 
a:: 150 
w 
"' 
" 
" z 
100 
10 
Retinopathy 
40 
82 
93 
128 
D WITHOUT RETINOPATHY 
~ WITH RETINOPATHY 
No retinopathy 
34 
56 
56 
52 
1otol dosage 1n · gms. Total dosage in gms 
Fig. 6 
Relationship between retinopathy and total dose in grammes 
a) number of patients 
b) in percentages 
Total 
74 
138 
149 
180 
The percentage of retinopathy is different in the various groups and increases. 
significantly as the average daily dose increases. (X~ = 8.40. P = 0.04). See also 
Fig. 7. 
The relationship between the duration of the phenothiazine treatment and the· 
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Relationship between retinopathy and average daily dose in mg 
a) number of patients 
b) in percentages 
:retinopathy is as follows: 
Duration of 
treatment 
in months 
< 10 
10-19 
20-39 
40-89 
> 90 
TABLE X 
Retinopathy and duration of phenothiazine treatment 
Retinopathy No retinopathy 
40 38 
46 42 
66 40 
113 43 
78 35 
45 
Total 
78 
88 
106 
156 
113 
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Relationship between retinopathy and duration of treatment 
a) number of patients 
b) in percentages 
The percentage of retinopathy is different in the various groups and shows a 
highly significant increase as the duration of the treatment increases. (z2 = 16. 72, 
P = 0.002). See also Fig. 8. 
If these data are tested by Kendall"s rank correlation technique with paired 
replicates the conclusions are the same: there is a highly significant rise in the 
probability of retinopathy as the dose of phenothiazine preparations which the 
patient has taken becomes higher and as the duration of treatment becomes 
longer. 
Visual acuity 
408 patients had normal visual acuity in both eyes, i.e. I 0/10 with or without 
correction of refractive errors. 160 of these patients (320 eyes) had no retino-
pathy and 248 (496 eyes) had retinopathy. 17 patients without retinopathy had 
normal visual acuity in one eye (10 right eyes and 7 left eyes). 45 patients with 
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retinopathy had normal visual acuity in one eye (25 right eyes and 20 left eyes). 
Visual acuity of less than 10/10 was found in 59 eyes without retinopathy and 
in 145 eyes with retinopathy. To summarize: 
With retinopathy 
Without retinopathy 
Total 
TABLE XI 
Visual acuity 
Eyes with visual acuity 
less than 10/10 
145 
59 
204 
Eyes with 
normal vision 
541 
337 
878 
Tota 
686 
396 
1.082 
Visual acuity less than 10/10 was found in 21.1% of the group with retinopathy 
and in 14.9% of the group without retinopathy. For all the patients included in 
this study the figure is 18.9% with visual acuity less than 10/10. 
71.1 % of the patients with poor visual acuity had retinopathy and 28.9% had 
no retinopathy. 61.6% of the patients with normal visual acuity had a retino-
pathy and 38.4% no retinopathy. 
Colour vision 
Lack of co-operation on the part of the patients made it impossible to perform 
colour tests on 14 men and 45 women. Colour defects of various types were found 
in 17 men. i.e. 6.9% of the 246 men investigated. Eight of these were protans. 
seven deutans and two unclassified. None of the women had colour defects. 
Classification of the 17 men with colour defects by the degree of retinopathy 
yields the following results: 
TABLE XII 
Colour defects 
Colour defect Normal retina Slight Severe Total 
retinopathy retinopathy 
Pro tans 1 6 8 
Deutans 0 5 2 7 
Unclassified 0 2 0 2 
Total 13 3 17 
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Electro-oculogram 
An EOG investigation was attempted on a number of patients and the results 
in 93 cases were considered to be reliable. In order to get better insight into the 
results obtained, the investigation was also carried out on a group of 23 normal 
subjects of approximately the same age as the patients. These results appear in 
the table below as "Control Group·. 
At the time of this study 135 %*was considered to be the lower limit of normal 
for the LP/DT ratio, with a standard deviation of20%. The results can thus be 
divided into three groups: 
I. Normal EOG with LP/DT ratio~ 205%: 
2. Doubtful: 
a) probably normal EOG with LP/DT ratio of 185-205%. 
b) probably subnormal EOG with LP/DT ratio of 165-185%: 
3. Subnormal EOG with LP/DT ratio,;; 165%. 
TABLE XIII 
Results of EOG investigation (figures represent number of eyes) 
LP/DT ratio 
% 
< 165 
165- 205 
> 205 
Total 
Control 
group 
2 
18 
26 
46 
No 
retinopathy 
7 
19 
16 
42 
Phenothiazine group 
SI;ght Severe 
retinopathy retinopathy 
23 11 
54 9 
35 12 
112 32 
The percentage of pathological EOG"s in the control group is 4.3 %. in the 
phenothiazine group without visible anomalies 16.7%. in the group with slight 
retinopathy 20.5% and in the group with severe retinopathy 34.4 %. See also 
Fig. 9. 
"* 165% is now the accepted ratio (1969. VAN LITH & BALIK. to be published). 
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Comparison of the phenothiazine group with the control group shows that the 
percentage of pathological EOG "s is significanrly higher in the former group 
(z' ~ 13.6, P ~ 0.01). 
DISCUSSION 
Before considering the results in detail. some explanation is necessary of the 
way in which the total dose and the average daily dose of the phenothiazine 
preparations have been calculated. These figures were arrived at by simply 
adding up the amounts of the different phenothiazine preparations in grammes 
which the patient had taken. 
The most ideal situation would be if a patient had only taken one pheno~ 
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thiazine preparation. In our complete patient material this was only the case 
seven times. The other patients had all been given a combination of preparations 
or the preparation prescribed had been changed in the course of treatment. 
If one considers the phenothiazine preparations which are included in this 
study, they can be roughly divided into preparations which are given in high 
dosage and those which are given in low dosage. For each preparation there is a 
minimum dose which is still just therapeutically active. It would be possible to 
call this dose K and to express. for each preparation. the amount which had 
been taken in this factor K. It is. however, extremely difficult to decide upon the 
value of K for each preparation: for example. the average daily dosage of 
promazine Suggested by GOODMAN & GILMAN is 500-1,000 mg., by KIELHOLZ 
100-600 mg.~ for chlorpromazine. GOODMAN & GILMAN 300-800 mg., KIELHOLZ 
75-500 mg. Furthermore, there are objections to equating the pharmacodynam-
ic action of different drugs, as it is known that the active components of various 
preparations have different points of action in the organism. In addition, it was 
not our intention in this study to compare the pharmacological and pharma-
codynamic actions of the various phenothiazine preparations on the psyche, but 
to estimate their retinotoxicity. Although arguments can undoubtedly be ad-
vanced against simply adding up the amounts of phenothiazine preparations 
t~ken per patient, the advantages of a simple procedure seem to us to be evident. 
Skin pigmentations 
These were only observed in female patients (0.9 %). Originally it was thought 
that the slate-blue discoloration was only found in women, possibly because of 
hormonal infiuence(GREINER & BERRY, 1964). Later, however, it appeared that 
male patients could also be affected (BAN & LEHMANN. 1965). These authors found 
fifteen cases of skin pigmentation among 1,500 patients (1 %) and called this 
phenomenon ·a rare side-effect of chlorpromazine'. According to RIVES & 
PELLERAT (1966), skin pigmentations occur in less than I j/00• 
The discoloration is caused by melanin~containing cells in the deeper layers 
of the stratum spinosum. stratum basalis and corium (GUNBY. 1966). HASHIMOTO 
(1966) found ·an increased number of melanin granules and round or bizarre-
shaped bodies in the lysosomes of the large phagocytes of the dermis as well as 
of the endothelial and perithelial cells of the dermal blood vessels'. ZELICKSON 
( 1964, 1965, 1966) calls these dense bodies "drug metabolite· consisting of pseudo-
melanin or some other form of pigment. 
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PERRY. CULLING. BERRY & HANSEN (1964) COnsider that ultraviolet light causes 
the production of a toxic compound from a 7-hydroxylated chlorpromazine 
derivative in the skin. cornea and lens, which is responsible for the increased 
melanin production. They were able to isolate 7-hydroxychlorpromazine from 
the liver and urine of patients who had been treated with large doses of chlor-
promazine for long periods of time. They observed that 7-hydroxychlorproma-
zine rapidly turned purple both in solution and on paper chromatograms after 
brief exposure to sunlight and wondered if this metabolite might be responsible 
for the photosensitive purplish pigmentation of the skin. 
SATANOVE (1965. 1967) with his 'skin window· technique. saw the transporta-
tion of pigment to the blood vessels by leucocytes and macrophages. 
Cornea and lens 
As we unfortunately had no hand slit-lamp. only a few patients were able to 
undergo slit-lamp examination. When this was essential the patients had to be 
transported to one of the Eye Hospitals. which made extra work for the nursing 
staff. 
This will be the reason why such a small number of corneal (1.5%) and lens 
{8.5 %) opacities were found; only the most pronounced lens opacities could be 
seen with transmitted light without a slit-lamp. In the literature, however. the 
findings vary greatly: from 0% (SARIN eta!., 1966) to 85.1% (SANDVIG, !965). 
In our material opacities of the lens and cornea were found by a total dosage 
of phenothiazine preparations lower than 500 gm .. which is not in agreement 
with the findings of DELONG et al. (1965). No conclusion could be drawn about 
any influence of the total dosage, average daily dose or duration of the treatment 
on the incidence of corneal and lens opacities (see Table 2). 
Of the eight cases with corneal anomalies one had no lens opacities, the other 
seven cases had both lens and corne:::tl opacities. 
Concerning the nature of these opacities. NOURI & CUENDET (1968) have sug-
gested that they are formed of iris pigme:1t. They punctured the anterior cham-
ber of a patient with corneal and lens anomalies and found iris pigment in the 
aspirated aquc::>Us. 
In addition, the situation of the opacities suggests pigment: pigrr.cnt in the 
anterior chamber is usually precipitated in the pupil space (ADLER. 1965). On 
the other hand, NORDMANN (personal communication. 1969) maintains that 
iris pigment in only found on the lens capsule. not in the capsule or lens. 
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The only publication in which opacities in the posterior capsule of the lens 
due to phenothiazine preparations are mentioned is that of MCDONALD (I 967). 
His observations were, however. on guinea pigs: opacities at the back of the lens 
in man have not been described. 
KASSMAN (1967) has drawn attention to the resemblance between the pheno-
thiazine cataract and Vogfs 'Sonnenblumenstar· which occurs in \Vilson"s 
disease and in the presence of an intra-ocular foreign body containing copper. 
The skin pigmentations and extra-pyramidal signs occurring during pheno-
thiazine treatment also resemble those seen in Wilson's disease (Annotation 
Lancet !965). 
Intra-ocular pressure 
The atropine-like action of the phenothiazines tends to cause a dilated pupiL so 
that in elderly patients with a narrow chamber angle there is an increased chance 
of glaucoma. In the small proportion of cases in which the intra-ocular pressure 
was measured. however. no harmful influence of the phenothiazines on the 
pressure could be observed. 
Rerinopath}' 
The term 'retinopathy" is not defined in the majority of text-books. The follow-
ing definition seems to be acceptable: retinopathy is a condition of the retina in 
which the anatomy and/or physiology is abnormaL with the exception of here-
ditary conditions (dystrophy) and inflammatory conditions. 
The retinal anomalies found in patients treated with phenothiazine prepara-
tions fall under this definition and one may therefore speak of a phenothiazine 
retinopathy. 
The number of retinopathy cases found in our patient material is high 
(63.4 %) compared with the percentages in the literature: 
APPELBAUM 
BARSA 
BAUMANN 
DELONG 
EDLER 
GOAR 
HAGOPIAN 
0 in 70 patients 
0 in 658 patients 
possibly 2 in 35 patients 
0 in 131 patients 
14 in 261 patients 
28 in 34 patients 
8 in 164 patients 
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RINTELEN 24 in 62 patients 
SARIN 0 in 34 patients 
SIDDALL 15 in 50 patients 
VERREY 24 in 78 patients 
WEEKLEY 4in 29 patients 
The majority of authors. however. have regarded clumping of pigment and 
marked depigmentations as the criteria for retinopathy: only SIDDALL (1965) 
speaks of ·granularity of pigment'. 
In our study coarsening of the pigment pattern of the retina was taken as the 
criterion for retinopathy. 
Retinopathy is found in our patient material in approximately the same 
percentage in men above and below 45 years of age and in women above the age 
of 45 (67.0%. 70.6%. 76.3%). In the group of women below the age of 45, 
however, retinopathy was found in only 36.5 %. Possible explanations of this 
could be that the patients had, on the average. been given a lower dosage of 
phenothiazine preparations or that the duration of the treatment had been 
shorter. Neither of these possibilities, however, could be established as the 
explanation of the low percentage of retinopathy in women under the age of 45. 
Both in the group where the retinopathy was called 'slight" and in the 'severe' 
retinopathy group the condition was seen most frequently affecting the whole 
fundus (central +peripheral) (Fig. 3 and Table 5). From the data on the locali-
zation of the retinopathy and the age and sex of the patient no conclusions can 
be drawn. 
POTTS. WEST & SHEARER (I 959) using various monochromatic filters in the 
television ophthalmoscope, were able to show that the pigmentations in retino-
pathy lie deep in the retina. 
Using panchromatic film material. CRAANDIJK & AAN DE KERK (1969) were able 
to photograph lesions in the deeper layers of the retina. This technique was also 
used on one of our patients with retinopathy of the macula. The photograph 
made with orthochromatic film shows a slight degree of retinopathy, whereas 
the photograph with panchromatic film shows that a much larger area is affected. 
(See photographs). 
For information about the nature of the retinopathy we are as yet dependent 
on animal experiments: post-mortem examination of a human eye has not been 
performed. This would be desirable in order to supplement our knowledge of the 
condition. 
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Extensive experiments performed by CERLETTI & MEIER-RUG£ (1967) and POTTS 
(1962) on cats, rabbits and hamsters have shown that some phenothiazine deriva-
tives are absorbed selec.tively on the melanin of the choroid, with resultant 
severe disorganization of the function of the choriocapillaris. This leads to 
degeneration of the distal segment of the rods and the formation of lipoid in the 
pigment epithelium. Later the cones are also affected. 
The toxic action of phenothiazine derivatives on the human eye may be differ-
ent from the effect on the cat. Among our patients cases were seen in which the 
retinopathy affected the macula only, where cones form the majority of photo-
receptors. 
Visual acuity 
In our codification scheme patients with visual acuity less than I 0/10 were also 
given a number for the cause of the anomaly: corneal lesions. opacities in lens or 
vitreous. lesions of the optic nerve and retinal lesions other than phenothiazine 
retinopathy. If none ofthese anomalies could be found the poor vision was coded 
under a separate number: poor vision of unknown origin. Retinopathy was not 
assumed to be a cause of poor visual acuity. A difficulty was that the determina-
tion of the refraction in some patients was very difficult owing to lack of co-
operation. 
This group of poor vision without an obvious cause comprised 84 eyes: 21 of 
these (25 %) had no retinopathy, 28 (33.3 %) had slight retinopathy and 35 
{47.7%) had severe retinopathy. 
The incidence of retinopathy in the whole patient material is: 396 (36. 6 %) 
without retinopathy. 454 (42 %) with slight retinopathy and 232 (21.4 %) with 
severe retinopathy. Comparison of the two groups shows a distinct shift in the 
group of poor vision of unknown origin towards severe retinopathy. 
It would thus appear possible that retinopathy may cause deterioration of 
vision. A definite conclusion. however. cannot be drawn from our material as 
there arc so many uncertain factors in the determination of the visual acuity. 
especially in psychiatric patients. 
Colour defects 
WAARDENBURG's (1963) figure for the incidence of colour defects in men is 
6.58-9.0 %. The incidence in our material. 6.9 %. is in good agreement with this 
figure. 
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According to WAARDENBURG the incidence of protans varies between 0.95% 
and 2.54% and the incidence of deutans between 5.08% and 6.80 %. In our 
material, however, we found 3.3% protans. 2.8% deutans and 0.8% unclassified. 
Seven of the eight protans had retinopathy. It seems probable that the pheno-
thiazine intoxication plays an important part in the explanation of the occurrence 
of these colour defects. 
Electro-oculogram 
The electro-oculogram provides information about the quality of the chorio-
capillaris. the pigment epithelium. Bruch ·s membrane and the retinal rods and 
cones. The results of the EOG investigation of patients taking phenothiazine 
preparations show that these tissues are unfavourably influenced by these drugs. 
It also appears that. as the retinopathy becomes more severe. the LP/DT ratio 
shifts further towards pathological values*. 
LP/DT ratio 
% 
< 165 
165-205 
> 205 
TABLE XIV 
EOG results in percentages 
Control group Phenothiazine group 
4.3 
39.1 
56.6 
No 
retino-
pathy 
16.7 
45.2 
38.1 
Slight Severe 
retino- retino-
pathy pathy 
20.5 34.4 
48.2 28.1 
31.3 37.5 
Phenothiazine 
group (total) 
22.0 
44.1 
33.9 
The results obtained by MATHALONE (I 967) who only gives one EOG value per 
patient, also point in the same direction. His results are given here, rearranged 
into groups as above. 
TABLE XV 
EOG results (Mathalone) 
< 165% 3 
165-205% 6 
> 205% 3 
Total 12 
* HENKES (1967, 1968) reported on a small group of these patients. 
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Fluorescein angiography 
One clear case of phenothiazine retinopathy was examined after 5 cc. 10% 
fluorescein solution had been injected into the antecubital vein. A modified 
Zeiss camera was used (Arend-van Gogh electronic flash unit and chronograph). 
A Schott filter GG 14 was used at the film plane and a Baird Atomic B4 inter~ 
ference filter before the electronic flash: the film was Ilford FP-3 (technique 
described by CRAANDIJK, I 968). No abnormalities were seen in the photographs. 
KRILL, NEWELL & CHISHTI (1968) performed fluorescein angiography on a 
41-year-old patient with phenothiazine retinopathy following thioridazine 
treatment. The daily dosage had been L600 mg. for 1 112 months followed by 
600 mg. for two weeks. The treatment was then stopped because the patient 
complained of poor vision. 
After the fluorescein had been injected (10 cc. 5% solution) the choroidal 
vessels were seen to be narrower than before the injection. Fluorescence was 
also seen at the posterior pole of the eye, which showed variations in intensity. 
This diffuse fluorescence became more uniform in brightness and easier to see 
by the late venous phase. 
These very different results may possibly be due to the use of different filters. 
but are probably dependent upon the severity of the pigment changes. Our 
patient showed coarsening of the pigment pattern only, whereas Krill"s patient 
had ·pigment clumps of various sizes and larger coalescent pigment plaques 
having the appearance of naevi". 
DIFFERENTIAL DIAGNOSIS 
1. Other iatrogenic retinopathies. 
a. Retinopathy caused by chloroquine and hydroxy-chloroquine. Here also 
coarsening of the pigment pattern of the fundus is seen. In severe cases the 
optic discs are pale, the blood vessels are narrow and the so-called "bulrs 
eye· fundus is seen. The case history is important. 
b. Secondary pigmentary degeneration after smallpox vaccination. This 
retinopathy is restricted to the periphery and the pigment pattern is 
coarser. 
c. Retinopathy caused by atoxyl, optochine, eucupine. septojod. These 
drugs are no longer used (see pp. 13-17). 
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2. Infectious retinopathies: 
a. Congenital syphilis. The pepper-and-salt fundus is usually peripheraL 
b. Secondary syphilis. The pigment pattern is usually coarser. 
c. Secondary pigmentary degeneration following rubella. This is. as Lb ... 
restricted to the periphery. 
d. Secondary pigmentary degeneration after measles. 
e. Retinopathy in Beh<;efs disease (this disease is considered by some autho-
rities to be an infection by an unknown agent). 
f. Pigmented scars in the retina in Toxoplasmosis. These are usually much 
coarser. 
g. Retinopathy following typhoid fever. 
3. Senile pigmentary changes and changes due to arteriosclerosis and arteriolo-
sclerosis. These are usually peripheral but are also found in the central area. 
They are usually not seen under the age of 45 years. 
4. Tapeto-retinal degeneration ('retinitis pigmentosa ").The typical 'bone corpus-
cle" structure seen in the peripheral form of this disease is not seen in pheno-
thiazine retinopathy. 
THERAPY 
The lightening effect of d-penicillamine on the skin pigmentations caused by 
phenothiazines has been described by NICOLSON et al. (1966). This substance is 
also reported to have a favourable influence on the patient's psychiatric condi-
tion. 
These observations led us to investigate the effect of d-penicillamine* on the-
retinal pigmentations. Five women and four men with marked retinopathy 
were treated with 900 mg. d-penicillamine per day for four periods of six days_ 
On the seventh day they were given 2 
of: 
FeS0,.7H,O 
MgC1 2.7H':!O 
Co(N0,),.6H,O 
ZnS0.,.7H,O 
MnS0,.7H,O 
~< 30 ml. of a mineral 'cocktail" consisting 
1.0 gr. in 
0.5gr. 
0.2 gr. 
0.2 gr. 
0.2 gr. 
1 litre aq. dest. 
-do-
- do-
-do-
-do-
The patients were given a copper-free diet. 
* provided by Mycofarm Delft (Koninklijke Nederlandsche Gist- en Spiritus-
fabriek N.Y.) 
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Before the experiment was started fundus photographs and EOG"s were made. 
the latter was only successful in three cases. A month later the fundus photo-
graphs and EOG"s were repeated. The nursing and medical staff were asked to 
observe the patients carefully during this month. This experiment was carried 
-out in the winter in order to reduce the effect of sunlight as far as possible. 
Results 
The fundus photographs were unchanged. the EOG"s had not improved and the 
patients" behaviour was unaltered in the month of treatment. 
The duration of the experiment may have been too short. MATHALONE (1967) 
-also working with d-penicillamine, extended the experiment over eight months. 
Some improvement was seen in three patients with corneal opacities from the 
_group of ten patients treated. 
CONCLUSIONS 
From this study it appears that the administration of phenothiazine deriva-
1ives to psychiatric patients. varying in age from 17 to 81 years, gives rise to: 
a. Discoloration of the skin, where it is exposed to the sun. in 0.9% of cases. 
These were all women. 
b. Photosensitivity in 9.1% of cases. This phenomenon was observed equally in 
men and women. 
c. Corneal opacities in the form of fine yellowish-white granules in the stroma 
and Descemet"s membrane and in and on the endothelium. 
d. Lens opacities. granular. on and in the anterior capsule of the lens. 
-e. Retinopathy in the form of coarsening of the pattern of the pigment epithe-
lium. This was seen in 63.4% of cases. In women under 45 years of age the 
percentage was lower (36.5 %) : no explanation could be found for this. 
It was impossible to ascribe a more pronounced retinotoxic action to one 
or more specific phenothiazine preparations. because nearly all the patients 
had been treated with more than one preparation. 
Severe retinopathy usually affects the whole retina. Increase in the total 
dose of phenothiazine preparations taken leads to a highly significant rise in 
the incidence of retinopathy. The probability of retinopathy increases signi-
ficantly as the average daily dosage becomes larger. There is a highly signi-
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ficant rise in the probability of retinopathy as the duration of the treatment 
becomes longer. 
f. Possibly deterioration of vision. 
g. An abnormally high proportion of protans in the group of patients with 
colour defects. 
h. Disturbance of the standing potential of the eye. The LP/DT ratio of the 
EOG shifts significantly towards pathological values. 
The significance of the EOG. as an early diagnostic aid for the detection of an 
incipient retinopathy during phenothiazine treatment, has not yet been definitely 
established. but it is certainly of value as a supplementary aid. 
In this study serious defects in the visual function of patients treated with 
phenothazine preparations were not found. The occurrence of a retinopathy. 
however. which becomes more severe when the drugs are administered in higher 
dosage or for a longer period of time. suggests that caution is indicated. As 
long as there are no new therapeutic measures. it is possible that these patients 
will continue to take phenothiazine derivatives for many years, so that an 
investigation over a longer period of time. partly in the form of a follow-up of 
the present materiaL would be a sensible procedure. 
SUMMARY 
Publications about the retinotoxic action of phenothiazine derivatives led the 
author to undertake an ophthalmological investigation in two psychiatric 
hospitals in The Netherlands. 
The pharmacological actions of phenothiazine preparations are listed and a 
survey of the phenothiazine derivatives which are at present in use is given. 
Some retinotoxic substances are discussed and a survey is given of the litera-
ture on the ocular complications of phenothiazine therapy. 
The eyes of 561 patients were examined. of whom 541 are included in this 
study. 343 of these patients(63.4 %) were found to have retinopathy. The correla-
tion between the retinopathy and the total dose of phenothiazine preparations 
taken. and between the retinopathy and the duration of treatment. was highly 
significant. The correlation between the retinopathy and the average daily dose 
taken was significant. 
The retinopathy was associated with a reduced standing potential of the eye. 
as determined by electro-oculography. It was possibly responsible for diminished 
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visual acuity in some cases, and for an abnormally large proportion of protans. 
in the group of patients with colour defects. 
It was not possible to ascribe a more severe retinotoxic action to one or more 
specific phenothiazine derivatives than to others. 
In the author's opinion regular examination of the eyes of patients who are 
being treated with phenothiazine preparations in high dosage and for for a long 
period of time is indicated. 
REsuME 
Apres avoir pris connaissance de reffet n~tinotoxique des dCrives de la phe-
nothiazine. I' auteur a entrepris des recherches dans deux h6t)itaux psychiatriques 
des Pays Bas. 
L 'action pharmacologique des preparations de phenothiazine est rappelee 
et Ies dCrivCs actuellement utilises sont passes en revue. 
Quelques substances r6tinotoxiques sont discut6es et la litt6rature concernant 
les complications oculaires observees au cours de traitements a Ia pheno-
thiazine est commentee. 
Les yeux de 561 patients ont ere examines. 541 d'entre eux entrent dans cette 
etude. Chez 343 de ces malades (63,4 %) on a observe une r~tinopathie. Les 
correlations entre la r6tinopathie d"une part. la dose totale de phenothiazine 
ou la duree du traitement d"autre part. etaient hautement significatives. La 
correlation entre Ia r6tinopathie et la dose moyenne journalihe Ctait significative. 
La retinopathie est associCe a une reduction du potentiel continu (standing 
potential) qui est determine par 1'6lectro-oculographie. Elle 6tait peut-etre 
aussi responsable de la diminution de racuit6 visuelle constatCe dans uncertain 
nombre de cas. et de la proportion anormalement 6lev6e de protanopes dans Ie 
groupe de malades atteints d'anomalies du sens chromatique. 
II 6tait impossible d'attribuer a certains d6riv6s de la phenothiazine un effet 
r6tinotoxique plus fort qu·a d'autres. 
Un examen oculistique r6gulier de malades qui emploient des preparations de 
phenothiazine pendant un temps plus long etjou en grandes doses, a 6t6 
indiqu6 d'apres rauteur. 
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ZUSAMMENF ASSUNG 
Nach Kenntnisnahme der VerOffentlichungen Uber den retinotoxischen Ein-
fluB der Phenothiazinderivatehat der Verfasser eine Untersuchungsreihe in zwei 
psychiatrischen Kliniken der Niederlande unternommen. 
Die pharmakologischen Eigenschaften von Phenothiazinpriiparaten werden 
aufgez3.hlt und die heute gebriiuchlichen Phenothiazinderivate im Einzelnen 
besprochen. 
Einige retinotoxische Substanzen werden diskutiert und es wird Uber die am 
Auge beobachteten Komplikationen der Phenothiazintherapie referiert. 
Die Augen von 561 Patienten wurden untersucht. 541 davon wurden in dieser 
Reihe beri.icksichtigt. Bei 343 von diesen Patient en (63.4 %) wurde eine Retino-
pathie festgestellt. Die Korrelationen zwischen der Retinopathie einerseits, der 
Gesamtdosis des verabreichten Phenothiazins oder der Behandlungsdauer 
andererseits waren in hohem MaGe signifikant. Die Korrelation zvvischen 
Retinopathie und mittlerer Tagesdosis war signifikant. 
Die Retinopathie ist mit einer Herabsetzung des elektro-okulographisch 
gemessenen Ruhepotentials (standing potential) verbunden. Sie ist mOglicher-
weise auch verantwortlich fUr die Sehkraftverminderung. die in einer gewissen 
Zahl von Fallen festgestellt wurde. und ebenso fi.ir den abnorm hohen Prozent-
satz von Protanopen. der in der Gruppe der Patienten mit FarbsinnstOrungen 
entdeckt wurde. 
Es war unmOglich bestimmter Phenothiazinderivate eine stiirkere retino-
toxische Wirkung zuzuschreiben als andere. 
RegelmiiBige augenheilkundige Untersuchung von Patienten. die langere Zeit 
{)der/und hOhere Dcsen Phenothiazinpriiparaten einnehmen ist nach der 
Meinung des Verfassers notwendig. 
SAMENVA TIING 
Publikaties betreffende de retinotoxische werking van enkele phenothiazine 
derivaten waren aanleiding tot bet instellen van een oogheelkundig onderzoek 
bij twee psychiatrische inrichtingen in Nederland. 
De pharmacologische werking der phenothiazinen wordt vermeld en een 
overzicht wordt gegeven van de huidig gebruikte derivaten. 
Enkele retinotoxische stoffen worden besproken. waarna een overzicht volgt 
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van de literatuur omtrent de oogheelkundige afwijkingen veroorzaakt door 
phenothiazinen. 
561 patienten werden oogheelkundig onderzocht. Hiervan moesten 20 patien-
ten worden afgevoerd. Van de resterende 541 patienten hadden 343 (63.4 %) een 
retinopathie. 
Deze retinopathie bleek sterk significant toe te nemen met de duur van de 
therapie, significant afhankelijk te zijn van de gemiddelde dagdosis en sterk 
significant toe te nemen met bet stijgen van de totale dosis phenothiazinen. 
De retinopathie ging gepaard met een daling van bet rustpotentiaal van bet 
oog. aangetoond door middel van elektro-oculografie. 
Mogelijk gaf de retinopathie in enkele gevallen aanleiding tot een visusdaling 
en veroorzaakte bet optreden van relatief te veel protans in de groep patienten 
met kleurzien stoornissen. 
Ret was onrnogelijk bepaalde phenothiazine derivativen een sterkere retino-
toxische werking toe te schrijven dan andere. 
Regelmatig oogheelkundig onderzoek van patienten die gedurende langere 
tijd en/of in hoge dosis phenothiazine preparaten gebruiken is volgens de auteur 
geindiceerd. 
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